ANVS
Annovis Bio, Inc.
Price Chart
Latest Quote
$1.74
-0.06 (-3.33%)
Current Price
| Previous Close | $1.80 |
| Open | $1.77 |
| Day High | $1.80 |
| Day Low | $1.72 |
| Volume | 475,439 |
Stock Information
| Shares Outstanding | 42.54M |
| Cash Equivalents | $14.22M |
| Net Income | $-40.92M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $74.02M |
| EPS (TTM) | $-1.71 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $46.07M |
| Income | $-40.92M |
| Book/sh | $0.11 |
| Cash/sh | $0.33 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 1.11 |
| Current Ratio | 1.27 |
Returns & Margins
| ROA | -120.18% |
| ROE | -301.13% |
Ownership
| Insider Ownership | 8.26% |
| Institutional Ownership | 16.47% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.97 |
| P/B | 15.82 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $11.00 |
Technical Indicators
| SMA20 | $1.82 |
| SMA50 | $1.93 |
| SMA200 | $2.52 |
| RSI | 51.25 |
| ATR | 0.1329 |
| Shares Float | 30.67M |
| Short Float | 12.55% |
| Short Ratio | 4.61 |
| Volatility | 1.19 |
| Rel Volume | 0.64 |
Performance History
| Week | -6.45% |
| Month | -2.79% |
| Quarter | -2.25% |
| 6 Months | -45.11% |
| YTD | -52.33% |
| Year | -36.50% |
| 3 Years | -87.26% |
| 5 Years | -98.34% |
| 10 Years | -81.86% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $1.74 | 624,100 |
| 2026-07-16 | $1.74 | 475,600 |
| 2026-07-15 | $1.80 | 465,300 |
| 2026-07-14 | $1.71 | 1,591,500 |
| 2026-07-13 | $1.76 | 969,200 |
| 2026-07-10 | $1.86 | 1,166,400 |
| 2026-07-09 | $1.95 | 1,048,400 |
| 2026-07-08 | $1.99 | 1,794,100 |
| 2026-07-07 | $1.92 | 1,628,100 |
| 2026-07-06 | $1.97 | 456,600 |
| 2026-07-02 | $1.93 | 958,300 |
| 2026-07-01 | $1.92 | 716,300 |
| 2026-06-30 | $1.86 | 667,900 |
| 2026-06-29 | $1.86 | 892,500 |
| 2026-06-26 | $1.72 | 1,364,400 |
| 2026-06-25 | $1.65 | 1,200,200 |
| 2026-06-24 | $1.70 | 756,000 |
| 2026-06-23 | $1.74 | 670,800 |
| 2026-06-22 | $1.77 | 815,500 |
| 2026-06-18 | $1.75 | 1,091,200 |
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
đ° Latest News
Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial
NYSE âĸ 2026-07-07T14:51:56Z
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
Simply Wall St. âĸ 2026-05-22T00:58:40Z
Annovis (ANVS) Secures Patent Coverage for Both Forms of Buntanetap
Insider Monkey âĸ 2025-08-29T11:24:59Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $29,695,258 | $26,694,928 | $45,035,011 | $25,511,279 |
| Other Income Expense | $142,000 | $3,625,893 | $-11,837,200 | - |
| Net Non Operating Interest Income Expense | $699,061 | $-1,521,340 | $667,898 | $182,712 |
| Operating Expense | $29,695,258 | $26,694,928 | $45,035,011 | $25,511,279 |
| General And Administrative Expense | $4,479,651 | $6,699,481 | $6,244,408 | $8,995,736 |
| Total Other Finance Cost | - | $1,853,189 | - | - |
| Other Operating Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-28,854,197 | $-24,590,375 | $-56,204,313 | $-25,328,567 |
| Net Interest Income | $699,061 | $-1,521,340 | $667,898 | $182,712 |
| Interest Income | $699,061 | $331,849 | $667,898 | $182,712 |
| Normalized Income | $-28,996,197 | $-28,216,268 | $-44,367,113 | $-25,328,567 |
| Net Income From Continuing And Discontinued Operation | $-28,854,197 | $-24,590,375 | $-56,204,313 | $-25,328,567 |
| Total Operating Income As Reported | $-29,695,258 | $-26,694,928 | $-45,035,011 | $-25,511,279 |
| Average Dilution Earnings | $0 | $-3,625,893 | $0 | - |
| Net Income Common Stockholders | $-28,854,197 | $-24,590,375 | $-56,204,313 | $-25,328,567 |
| Net Income | $-28,854,197 | $-24,590,375 | $-56,204,313 | $-25,328,567 |
| Net Income Including Noncontrolling Interests | $-28,854,197 | $-24,590,375 | $-56,204,313 | $-25,328,567 |
| Net Income Continuous Operations | $-28,854,197 | $-24,590,375 | $-56,204,313 | $-25,328,567 |
| Pretax Income | $-28,854,197 | $-24,590,375 | $-56,204,313 | $-25,328,567 |
| Interest Income Non Operating | $699,061 | $331,849 | $667,898 | $182,712 |
| Operating Income | $-29,695,258 | $-26,694,928 | $-45,035,011 | $-25,511,279 |
| Per Share | ||||
| Diluted EPS | $-1.40 | $-2.31 | $-6.23 | $-3.10 |
| Basic EPS | $-1.40 | $-2.02 | $-6.23 | $-3.10 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-29,837,258 | $-30,320,821 | $-33,197,811 | $-25,511,279 |
| Total Unusual Items | $142,000 | $3,625,893 | $-11,837,200 | - |
| Total Unusual Items Excluding Goodwill | $142,000 | $3,625,893 | $-11,837,200 | - |
| EBITDA (Bullshit earnings) | $-29,695,258 | $-26,694,928 | $-45,035,011 | $-25,511,279 |
| EBIT | $-29,695,258 | $-26,694,928 | $-45,035,011 | $-25,511,279 |
| Diluted Average Shares | $20,551,997 | $12,235,444 | $9,023,138 | $8,162,326 |
| Basic Average Shares | $20,551,997 | $12,182,475 | $9,023,138 | $8,162,326 |
| Diluted NI Availto Com Stockholders | $-28,854,197 | $-28,216,268 | $-56,204,313 | $-25,328,567 |
| Gain On Sale Of Security | $142,000 | $3,625,893 | $-11,837,200 | - |
| Research And Development | $25,215,607 | $19,995,447 | $38,790,603 | $16,515,543 |
| Selling General And Administration | $4,479,651 | $6,699,481 | $6,244,408 | $8,995,736 |
| Other Gand A | $4,479,651 | $6,699,481 | $6,244,408 | $8,995,736 |
| Provision For Doubtful Accounts | - | - | $0 | $0 |
Fetched: 2026-07-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $16,851,250 | $9,307,646 | $-7,750,846 | $28,323,530 |
| Total Assets | $21,081,625 | $13,925,633 | $10,208,264 | $36,022,069 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $21,081,625 | $13,925,633 | $10,208,264 | $36,022,069 |
| Prepaid Assets | $1,549,287 | $3,373,717 | $4,453,544 | $7,644,376 |
| Cash Cash Equivalents And Short Term Investments | $19,532,338 | $10,551,916 | $5,754,720 | $28,377,693 |
| Cash And Cash Equivalents | $19,532,338 | $10,551,916 | $5,754,720 | $28,377,693 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,230,375 | $4,617,987 | $17,959,110 | $7,698,539 |
| Total Non Current Liabilities Net Minority Interest | $595,000 | $737,000 | $13,680,000 | $0 |
| Derivative Product Liabilities | $595,000 | $737,000 | $13,680,000 | $0 |
| Current Liabilities | $3,635,375 | $3,880,987 | $4,279,110 | $7,698,539 |
| Payables And Accrued Expenses | $3,635,375 | $3,880,987 | $4,279,110 | $7,698,539 |
| Payables | $2,590,516 | $2,305,974 | $1,292,837 | $3,961,254 |
| Accounts Payable | $2,590,516 | $2,305,974 | $1,292,837 | $3,961,254 |
| Equity | ||||
| Common Stock Equity | $16,851,250 | $9,307,646 | $-7,750,846 | $28,323,530 |
| Total Equity Gross Minority Interest | $16,851,250 | $9,307,646 | $-7,750,846 | $28,323,530 |
| Stockholders Equity | $16,851,250 | $9,307,646 | $-7,750,846 | $28,323,530 |
| Retained Earnings | $-163,703,659 | $-134,849,462 | $-110,259,087 | $-54,054,774 |
| Other | ||||
| Ordinary Shares Number | $27,199,139 | $14,141,521 | $10,519,933 | $8,163,923 |
| Share Issued | $27,199,139 | $14,141,521 | $10,519,933 | $8,163,923 |
| Tangible Book Value | $16,851,250 | $9,307,646 | $-7,750,846 | $28,323,530 |
| Invested Capital | $16,851,250 | $9,307,646 | $-7,750,846 | $28,323,530 |
| Working Capital | $17,446,250 | $10,044,646 | $5,929,154 | $28,323,530 |
| Total Capitalization | $16,851,250 | $9,307,646 | $-7,750,846 | $28,323,530 |
| Additional Paid In Capital | $180,552,190 | $144,155,694 | $102,507,189 | $82,377,488 |
| Capital Stock | $2,719 | $1,414 | $1,052 | $816 |
| Common Stock | $2,719 | $1,414 | $1,052 | $816 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Accrued Expenses | $1,044,859 | $1,575,013 | $2,986,273 | $3,737,285 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-07-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-25,619,703 | $-21,894,604 | $-39,967,304 | $-17,312,934 |
| Operating Activities | ||||
| Operating Cash Flow | $-25,619,703 | $-21,894,604 | $-39,967,304 | $-17,312,934 |
| Cash Flow From Continuing Operating Activities | $-25,619,703 | $-21,894,604 | $-39,967,304 | $-17,312,934 |
| Operating Gains Losses | $-142,000 | $-3,625,893 | $11,837,200 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $34,598,126 | $18,666,797 | $16,885,946 | $0 |
| Financing Cash Flow | $34,600,125 | $26,691,800 | $17,344,331 | $4,613 |
| Cash Flow From Continuing Financing Activities | $34,600,125 | $26,691,800 | $17,344,331 | $4,613 |
| Net Common Stock Issuance | $34,598,126 | $18,666,797 | $16,885,946 | $0 |
| Common Stock Issuance | $34,598,126 | $18,666,797 | $16,885,946 | $0 |
| Other | ||||
| End Cash Position | $19,532,338 | $10,551,916 | $5,754,720 | $28,377,693 |
| Beginning Cash Position | $10,551,916 | $5,754,720 | $28,377,693 | $45,686,014 |
| Changes In Cash | $8,980,422 | $4,797,196 | $-22,622,973 | $-17,308,321 |
| Proceeds From Stock Option Exercised | $1,999 | $8,025,003 | $458,385 | $4,613 |
| Change In Working Capital | $1,578,818 | $681,705 | $-228,597 | $-1,136,887 |
| Change In Payables And Accrued Expense | $-245,612 | $-398,122 | $-3,419,429 | $6,192,025 |
| Change In Accrued Expense | $-530,154 | $-1,411,260 | $-751,012 | $2,918,845 |
| Change In Payable | $284,542 | $1,013,138 | $-2,668,417 | $3,273,180 |
| Change In Account Payable | $284,542 | $1,013,138 | $-2,668,417 | $3,273,180 |
| Change In Prepaid Assets | $1,824,430 | $1,079,827 | $3,190,832 | $-7,328,912 |
| Stock Based Compensation | $1,797,676 | $3,836,770 | $4,628,406 | $9,152,520 |
| Gain Loss On Investment Securities | $-142,000 | $-3,625,893 | $11,837,200 | - |
| Net Income From Continuing Operations | $-28,854,197 | $-24,590,375 | $-56,204,313 | $-25,328,567 |
| Other Non Cash Items | - | $1,803,189 | - | - |
| Change In Receivables | - | - | - | - |
Fetched: 2026-07-13